EnWave Corporation

EnWave Corporation

August 08, 2011 08:30 ET

EnWave Strengthens Intellectual Property Portfolio for nutraREV™ and powderREV™ Dehydration Technologies

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 8, 2011) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") announced today that the Company has strengthened its Intellectual Property ("IP") portfolio through the allowance of a key patent application for its nutraREV™ food dehydration technology. The Company has also filed a new patent application on its powderREV™ bulk biomaterial dehydration technology, and received a favourable report on patentability from the international Patent Cooperation Treaty ("PCT") Examiner on its first powderREV™ patent filed with the PCT in 2010. EnWave's business model provides exclusive testing rights and royalty-bearing licenses for products created using the Company's proprietary Radiant Energy Vacuum ("REV") dehydration technologies. Patents are the basis on which the Company is able to grant exclusivity of use to its multinational partners, all of whom are contributing to the introduction of this dehydration method to the global processing industry.

"We continue to make excellent progress through the gauntlet that is global intellectual property protection," stated Dr. Tim Durance, Chairman and Co-CEO, EnWave Corporation. "This is an ongoing, complex, expensive and time-consuming process, and one that is fundamentally important to our strategy of commercialization through partnerships with the world's largest food, biomaterials and pharmaceutical companies."

On July 11 2011, EnWave received a "Notice of Allowance" from the Canadian Intellectual Property Office ("CIPO") for its nutraREV™ equipment and method of use patent, meaning that the patent will now be issued in Canada. The Company expects that other jurisdictions around the world where this patent application was filed will follow suit in granting the patent, depending on their individual patent evaluation backlog. In January 2011, EnWave was granted a trademark in Canada and the U.S. for its nutraDRIED™ brand, and the Company is now working with several of its partners to develop co-branded nutraDRIED™ food products using REV technology. EnWave's goal is for nutraDRIED™ to become a recognizable standard in high-quality snack food and ingredients by consumers all over the world.

On July 25 2011, EnWave received the International Preliminary Report on Patentability ("IPRP") from the Patent Cooperation Treaty ("PCT") Examiner on the Company's first patent application for powderREV™ bulk biomaterial dehydration technology. The IPRP is the first official feedback that inventors receive on a patent application, and in this case the Examiner found all 18 claims in the patent application met the triple requirements of global novelty, inventiveness and industrial applicability. Although the PCT does not itself grant patents, the IPRP is forwarded by the PCT to each national patent office in which the Company will seek patent protection. A favorable IPRP is an important step towards eventually receiving an issued patent.

Finally, on July 19 2011, EnWave filed its third patent application in the United States on the commercial-scale design of its powderREV™ technology with claims related to equipment design and methods of use. If successful, this application will lead to patents which extend the Company's claims and control over this technology until 2031.

About EnWave

EnWave Corporation is a Vancouver-based industrial technology company developing commercial applications for its proprietary Radiant Energy Vacuum (REV) dehydration technology. In collaboration with an expanding list of multinational partners, including Nestlé, Kellogg's, Danisco, Grupo Bimbo, and Grimmway Farms, EnWave is introducing REV as a new dehydration standard in the food and biological material sectors: potentially faster and cheaper than freeze drying, with better end product quality than air drying or spray drying.

EnWave currently has six REV platforms: commercial-scale nutraREV™ and MIVAP™ are used in the food industry to dry fruits, vegetables, meat, herbs and seafood quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour. The Company is also developing powderREV™ for bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes; quantaREV™ for continuous, high-volume low-temperature drying of pastes, gels, liquids, or particulates; and bioREV™ and freezeREV™ as new methods to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation

Tim Durance, PhD, Chairman and Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. There is no guarantee that the Company's REV technology can or will improve processes in the target industry; even if the Company's REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's REV technology. All figures comparing REV technologies to freeze drying or other dehydration technologies are provided as examples of data obtained through the Company's own scientific and testing programs; each product must be tested individually to determine the benefits of using REV.

The TSX Venture Exchange has neither approved nor disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information